ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis
Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses. T lymphocytes express high levels of p110? and p110? class IA PI3K. Whereas the functioning of PI3K p110? in immune and autoimmune reactions is well established, the rol...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2016
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/26038
- Acceso en línea:
- https://doi.org/10.1016/j.bcp.2016.02.005
https://repository.urosario.edu.co/handle/10336/26038
- Palabra clave:
- T lymphocytes
CD28
ICOS
Phosphatidyl inositol-3 kinase
PI3K inhibitors
Rheumatoid arthritis
- Rights
- License
- Restringido (Acceso a grupos específicos)
id |
EDOCUR2_8eefc64f80d51baceda40fdc7838118c |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/26038 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
175531a3-a87d-4f50-81d7-b93272ef39d909bbecfb-59a5-4bea-b599-68e3a93b712ef68a9ea5-0fc2-4167-b307-b664e125c9c93836193360053eb2bb9-f0d0-4279-85f5-c7d98ba17d258839912c-dd88-4484-a998-1ff966dd3ff1bf02ce56-51b6-498d-a1e3-3ea0dba51fcb6bacd80e-8f91-4aef-b462-1b65301be0d0dc1a385a-bd83-4dae-aefc-375aa290b0c332a524b7-78e3-4fcd-8b3b-352d71ff22680d1e6f49-f17a-4fb7-82f8-659f07b1ab1eb9d8359d-2484-4cf2-8d1f-cf11725766cb2020-08-06T16:20:30Z2020-08-06T16:20:30Z2016-04-15Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses. T lymphocytes express high levels of p110? and p110? class IA PI3K. Whereas the functioning of PI3K p110? in immune and autoimmune reactions is well established, the role of p110? is less well understood. Here, a novel dual p110?/? inhibitor (ETP-46321) and highly specific p110? (A66) or p110? (IC87114) inhibitors have been compared concerning T cell activation in vitro, as well as the effect on responses to protein antigen and collagen-induced arthritis in vivo. In vitro activation of naive CD4+ T lymphocytes by anti-CD3 and anti-CD28 was inhibited more effectively by the p110? inhibitor than by the p110? inhibitor as measured by cytokine secretion (IL-2, IL-10, and IFN-?), T-bet expression and NFAT activation. In activated CD4+ T cells re-stimulated through CD3 and ICOS, IC87114 inhibited Akt and Erk activation, and the secretion of IL-2, IL-4, IL-17A, and IFN-? better than A66. The p110?/? inhibitor ETP-46321, or p110? plus p110? inhibitors also inhibited IL-21 secretion by differentiated CD4+ T follicular (Tfh) or IL-17-producing (Th17) helper cells. In vivo, therapeutic administration of ETP-46321 significantly inhibited responses to protein antigen as well as collagen-induced arthritis, as measured by antigen-specific antibody responses, secretion of IL-10, IL-17A or IFN-?, or clinical symptoms. Hence, p110? as well as p110? Class IA PI3Ks are important to immune regulation; inhibition of both subunits may be an effective therapeutic approach in inflammatory autoimmune diseases like rheumatoid arthritis.application/pdfhttps://doi.org/10.1016/j.bcp.2016.02.005ISSN: 0006-2952EISSN: 1873-2968https://repository.urosario.edu.co/handle/10336/26038engElsevier6956Biochemical PharmacologyVol. 196Biochemical Pharmacology, ISSN: 0006-2952;EISSN: 1873-2968, Vol.196 (2016); pp.56-69https://www.sciencedirect.com/science/article/abs/pii/S0006295216000848?via%3DihubRestringido (Acceso a grupos específicos)http://purl.org/coar/access_right/c_16ecBiochemical Pharmacologyinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURT lymphocytesCD28ICOSPhosphatidyl inositol-3 kinasePI3K inhibitorsRheumatoid arthritisETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritisETP-46321, un inhibidor dual de la fosfoinositida 3-quinasa p110? / ? clase IA modula la activación de los linfocitos T y la artritis inducida por colágenoarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Aragoneses-Fenoll, L.Montes-Casado, M.Ojeda, G.Acosta Ampudia, Yeny YasbleidyHerranz, J.Martínez, S.Blanco-Aparicio, C.Criado, G.Pastor, J.Dianzani, U.Portolés, P.Rojo, J.M.10336/26038oai:repository.urosario.edu.co:10336/260382022-05-02 07:37:13.54034https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis |
dc.title.TranslatedTitle.spa.fl_str_mv |
ETP-46321, un inhibidor dual de la fosfoinositida 3-quinasa p110? / ? clase IA modula la activación de los linfocitos T y la artritis inducida por colágeno |
title |
ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis |
spellingShingle |
ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis T lymphocytes CD28 ICOS Phosphatidyl inositol-3 kinase PI3K inhibitors Rheumatoid arthritis |
title_short |
ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis |
title_full |
ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis |
title_fullStr |
ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis |
title_full_unstemmed |
ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis |
title_sort |
ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis |
dc.subject.keyword.spa.fl_str_mv |
T lymphocytes CD28 ICOS Phosphatidyl inositol-3 kinase PI3K inhibitors Rheumatoid arthritis |
topic |
T lymphocytes CD28 ICOS Phosphatidyl inositol-3 kinase PI3K inhibitors Rheumatoid arthritis |
description |
Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses. T lymphocytes express high levels of p110? and p110? class IA PI3K. Whereas the functioning of PI3K p110? in immune and autoimmune reactions is well established, the role of p110? is less well understood. Here, a novel dual p110?/? inhibitor (ETP-46321) and highly specific p110? (A66) or p110? (IC87114) inhibitors have been compared concerning T cell activation in vitro, as well as the effect on responses to protein antigen and collagen-induced arthritis in vivo. In vitro activation of naive CD4+ T lymphocytes by anti-CD3 and anti-CD28 was inhibited more effectively by the p110? inhibitor than by the p110? inhibitor as measured by cytokine secretion (IL-2, IL-10, and IFN-?), T-bet expression and NFAT activation. In activated CD4+ T cells re-stimulated through CD3 and ICOS, IC87114 inhibited Akt and Erk activation, and the secretion of IL-2, IL-4, IL-17A, and IFN-? better than A66. The p110?/? inhibitor ETP-46321, or p110? plus p110? inhibitors also inhibited IL-21 secretion by differentiated CD4+ T follicular (Tfh) or IL-17-producing (Th17) helper cells. In vivo, therapeutic administration of ETP-46321 significantly inhibited responses to protein antigen as well as collagen-induced arthritis, as measured by antigen-specific antibody responses, secretion of IL-10, IL-17A or IFN-?, or clinical symptoms. Hence, p110? as well as p110? Class IA PI3Ks are important to immune regulation; inhibition of both subunits may be an effective therapeutic approach in inflammatory autoimmune diseases like rheumatoid arthritis. |
publishDate |
2016 |
dc.date.created.spa.fl_str_mv |
2016-04-15 |
dc.date.accessioned.none.fl_str_mv |
2020-08-06T16:20:30Z |
dc.date.available.none.fl_str_mv |
2020-08-06T16:20:30Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.bcp.2016.02.005 |
dc.identifier.issn.none.fl_str_mv |
ISSN: 0006-2952 EISSN: 1873-2968 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/26038 |
url |
https://doi.org/10.1016/j.bcp.2016.02.005 https://repository.urosario.edu.co/handle/10336/26038 |
identifier_str_mv |
ISSN: 0006-2952 EISSN: 1873-2968 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
69 |
dc.relation.citationStartPage.none.fl_str_mv |
56 |
dc.relation.citationTitle.none.fl_str_mv |
Biochemical Pharmacology |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 196 |
dc.relation.ispartof.spa.fl_str_mv |
Biochemical Pharmacology, ISSN: 0006-2952;EISSN: 1873-2968, Vol.196 (2016); pp.56-69 |
dc.relation.uri.spa.fl_str_mv |
https://www.sciencedirect.com/science/article/abs/pii/S0006295216000848?via%3Dihub |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_16ec |
dc.rights.acceso.spa.fl_str_mv |
Restringido (Acceso a grupos específicos) |
rights_invalid_str_mv |
Restringido (Acceso a grupos específicos) http://purl.org/coar/access_right/c_16ec |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Elsevier |
dc.source.spa.fl_str_mv |
Biochemical Pharmacology |
institution |
Universidad del Rosario |
dc.source.instname.none.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.none.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167554643460096 |